HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
102:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
summAry:@0.076182:0.087643:0.166728:0.087643:0.166728:0.067479:0.076182:0.067479:0.009609:0.011826:0.016631:0.016631:0.013674:0.010718:0.011457
The presence of albuminuria signifies a patient with silent :@0.076190:0.103532:0.485130:0.103532:0.485130:0.087750:0.076190:0.087750:0.006441:0.009223:0.009827:0.003160:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.003160:0.009903:0.004747:0.003160:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.003175:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009827:0.005866:0.003175:0.010326:0.003175:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.003160:0.012564:0.003024:0.005125:0.009223:0.003175:0.005866:0.003024:0.003024:0.009827:0.009223:0.005125:0.004188
but modifiable risk factors for chronic kidney disease and :@0.076190:0.117641:0.485145:0.117641:0.485145:0.101858:0.076190:0.101858:0.010311:0.009192:0.005125:0.002827:0.014182:0.009903:0.010357:0.003024:0.003681:0.003681:0.010326:0.010311:0.003024:0.009827:0.002842:0.004551:0.003024:0.005866:0.007590:0.002842:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.002827:0.004747:0.009903:0.004551:0.002827:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.002827:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.002842:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.002842:0.010326:0.009223:0.010357:0.004188
cardiovascular risk. All patients should undergo oppor-:@0.076190:0.131749:0.480942:0.131749:0.480942:0.115967:0.076190:0.115967:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005564:0.004551:0.003024:0.005866:0.007590:0.004188:0.005549:0.011188:0.003024:0.003024:0.005549:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005549:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005549:0.009192:0.009223:0.010357:0.009827:0.004551:0.010175:0.009903:0.005534:0.009903:0.010311:0.010311:0.009903:0.004551:0.005020
tunistic dipstick-testing of their urine for detection of :@0.076190:0.145858:0.485145:0.145858:0.485145:0.130075:0.076190:0.130075:0.005125:0.009192:0.009223:0.003024:0.005866:0.005125:0.003024:0.009782:0.008240:0.010357:0.003024:0.010311:0.005866:0.005125:0.003024:0.009782:0.007590:0.005020:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.010175:0.008240:0.009903:0.004747:0.008240:0.005125:0.009223:0.009827:0.003024:0.004551:0.008240:0.009192:0.004551:0.003024:0.009223:0.009827:0.008240:0.004747:0.009903:0.004551:0.008240:0.010357:0.009827:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.008240:0.009903:0.004747:0.004188
overt albuminuria, and if positive, should have an ACR :@0.076190:0.159966:0.485160:0.159966:0.485160:0.144184:0.076190:0.144184:0.009903:0.008376:0.009827:0.004551:0.005125:0.005186:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.004188:0.005201:0.010326:0.009223:0.010357:0.005201:0.003024:0.004747:0.005201:0.010311:0.009903:0.005866:0.003024:0.005125:0.003024:0.008376:0.009827:0.004188:0.005201:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005201:0.009223:0.010326:0.008376:0.009827:0.005201:0.010326:0.009223:0.005201:0.011188:0.012292:0.009177:0.004188
and eGFR  performed.  Further  investigation,  manage-:@0.076190:0.174075:0.480957:0.174075:0.480957:0.158292:0.076190:0.158292:0.010326:0.009223:0.010357:0.007529:0.009827:0.013184:0.007333:0.009177:0.004188:0.003326:0.010311:0.009827:0.004551:0.004747:0.009903:0.004551:0.014182:0.009827:0.010357:0.004188:0.004188:0.003326:0.007333:0.009192:0.004551:0.005125:0.009223:0.009827:0.004551:0.004188:0.003326:0.003024:0.009223:0.008376:0.009827:0.005866:0.005125:0.003024:0.010175:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003326:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.005020
ment and referral will depend on the level of ACR and :@0.076190:0.188183:0.485160:0.188183:0.485160:0.172401:0.076190:0.172401:0.014182:0.009827:0.009223:0.005125:0.004899:0.010326:0.009223:0.010357:0.004899:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.010326:0.003024:0.004883:0.012564:0.003024:0.003024:0.003024:0.004914:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.004899:0.009903:0.009223:0.004899:0.005125:0.009223:0.009827:0.004899:0.003024:0.009827:0.008376:0.009827:0.003024:0.004899:0.009903:0.004747:0.004899:0.011188:0.012292:0.009177:0.004899:0.010326:0.009223:0.010357:0.004188
eGFR. Patients with high cardiovascular risk, signified by :@0.076190:0.202292:0.485130:0.202292:0.485130:0.186509:0.076190:0.186509:0.009827:0.013184:0.007333:0.009177:0.004188:0.004294:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004294:0.012564:0.003024:0.005125:0.009223:0.004309:0.009223:0.003024:0.010175:0.009223:0.004294:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004309:0.004551:0.003024:0.005866:0.007590:0.004188:0.004309:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009827:0.010357:0.004309:0.010311:0.008104:0.004188
the presence of hypertension, diabetes, dyslipidaemia, :@0.076190:0.216401:0.485100:0.216401:0.485100:0.200618:0.076190:0.200618:0.005125:0.009223:0.009827:0.004702:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.004702:0.009903:0.004747:0.004702:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009207:0.004188:0.004702:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004702:0.010357:0.008104:0.005866:0.003024:0.003024:0.010311:0.003024:0.010357:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188:0.004188
smoking or overt cardiovascular disease, should under-:@0.076190:0.230509:0.480957:0.230509:0.480957:0.214726:0.076190:0.214726:0.005866:0.014182:0.009903:0.007590:0.003024:0.009223:0.010175:0.004687:0.009903:0.004551:0.004687:0.009903:0.008376:0.009827:0.004551:0.005125:0.004687:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004702:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004702:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004687:0.009192:0.009223:0.010357:0.009827:0.004566:0.005020
go an ACR for detection of micro-albuminuria to detect :@0.076190:0.244618:0.485160:0.244618:0.485160:0.228835:0.076190:0.228835:0.010175:0.009903:0.003568:0.010326:0.009223:0.003568:0.011188:0.012292:0.009177:0.003568:0.004747:0.009903:0.004551:0.003568:0.010357:0.009827:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.003568:0.009903:0.004747:0.003568:0.014182:0.003024:0.009782:0.004551:0.009903:0.005020:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.003568:0.005125:0.009903:0.003568:0.010357:0.009827:0.005125:0.009827:0.009782:0.005125:0.004188
a major additional risk factor for cardiovascular mortal-:@0.076190:0.258726:0.480942:0.258726:0.480942:0.242944:0.076190:0.242944:0.010326:0.004505:0.014182:0.010326:0.003069:0.009903:0.004551:0.004505:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004505:0.004551:0.003024:0.005866:0.007590:0.004505:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.004490:0.004747:0.009903:0.004551:0.004505:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004505:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.005020
ity, myocardial infarction, stroke and heart failure, and :@0.076190:0.272835:0.485115:0.272835:0.485115:0.257052:0.076190:0.257052:0.003024:0.005125:0.008104:0.004188:0.005292:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.005292:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005277:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.005277:0.010326:0.009223:0.010357:0.005292:0.009223:0.009827:0.010326:0.004551:0.005125:0.005277:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005292:0.010326:0.009223:0.010357:0.004188
chronic kidney disease in diabetics. Aggressive cardio-:@0.076190:0.286943:0.480942:0.286943:0.480942:0.271161:0.076190:0.271161:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.005020:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.005020:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005035:0.003024:0.009223:0.005020:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005866:0.004188:0.005020:0.011188:0.010175:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.008376:0.009827:0.005020:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020
vascular risk protection should be undertaken.:@0.076190:0.301052:0.413511:0.301052:0.413511:0.285269:0.076190:0.285269:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.004551:0.003024:0.005866:0.007590:0.004188:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188:0.010311:0.009827:0.004188:0.009192:0.009223:0.010357:0.009827:0.004551:0.005125:0.010326:0.007590:0.009827:0.009223:0.004188
referenCes:@0.076190:0.333946:0.182628:0.333946:0.182628:0.313781:0.076190:0.313781:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.345840:0.089220:0.345840:0.089220:0.333565:0.076190:0.333565:0.006515:0.003257:0.003257
Chronic  Kidney Disease  prognosis Consortium,  Matsushita K,  van :@0.101390:0.345840:0.484213:0.345840:0.484213:0.333565:0.101390:0.333565:0.009560:0.007173:0.003540:0.007702:0.007173:0.002352:0.007608:0.003257:0.002364:0.006950:0.002352:0.008055:0.007173:0.007644:0.006303:0.005633:0.008749:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.002375:0.006961:0.003540:0.007702:0.007914:0.007173:0.007702:0.004563:0.002340:0.004563:0.005633:0.009560:0.007702:0.007173:0.004563:0.007702:0.003540:0.003986:0.002352:0.007150:0.011030:0.003257:0.003257:0.002364:0.010807:0.008032:0.003986:0.004563:0.007150:0.004563:0.007173:0.002352:0.003986:0.008032:0.005633:0.006950:0.003257:0.003257:0.002364:0.006515:0.008032:0.007173:0.003257
der Velde M, Astor  BC, Woodward  M, :@0.101390:0.356742:0.332083:0.356742:0.332083:0.344467:0.101390:0.344467:0.008055:0.007644:0.003540:0.005656:0.008255:0.007644:0.002352:0.008055:0.007644:0.005656:0.010807:0.003257:0.005656:0.008702:0.004563:0.003986:0.007702:0.003540:0.003257:0.002387:0.006750:0.009560:0.003257:0.005656:0.011289:0.007702:0.007702:0.008055:0.009772:0.008032:0.003540:0.008055:0.003257:0.002387:0.010807:0.003257:0.003257
et al:@0.334482:0.356742:0.362152:0.356742:0.362152:0.344467:0.334482:0.344467:0.007644:0.003986:0.005656:0.008032:0.002352
. Association of esti-:@0.362152:0.356742:0.480956:0.356742:0.480956:0.344467:0.362152:0.344467:0.003257:0.005656:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.005656:0.007702:0.003692:0.005656:0.007644:0.004563:0.003986:0.002352:0.003904
mated glomerular filtration rate and albuminuria with all-cause and :@0.101390:0.367643:0.484189:0.367643:0.484189:0.355368:0.101390:0.355368:0.011030:0.008032:0.003986:0.007644:0.008055:0.002857:0.007914:0.002352:0.007702:0.011030:0.007644:0.003540:0.007150:0.002352:0.008032:0.003540:0.002857:0.002863:0.002863:0.002352:0.003986:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.002857:0.003540:0.008032:0.003986:0.007644:0.002857:0.008032:0.007173:0.008055:0.002857:0.008032:0.002352:0.008020:0.007150:0.011030:0.002352:0.007173:0.007150:0.003540:0.002352:0.008032:0.002857:0.009772:0.002352:0.003986:0.007173:0.002857:0.008032:0.002352:0.002352:0.003904:0.007608:0.008032:0.007150:0.004563:0.007644:0.002869:0.008032:0.007173:0.008055:0.003257
cardiovascular mortality in general population cohorts: A collabo-:@0.101390:0.378545:0.480956:0.378545:0.480956:0.366269:0.101390:0.366269:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003857:0.011030:0.007702:0.003540:0.003986:0.008032:0.002352:0.002352:0.003986:0.006303:0.003857:0.002352:0.007173:0.003857:0.007914:0.007644:0.007173:0.007644:0.003540:0.008032:0.002352:0.003857:0.008020:0.007702:0.008020:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003857:0.007608:0.007702:0.007173:0.007702:0.003540:0.003986:0.004563:0.003257:0.003845:0.008702:0.003857:0.007608:0.007702:0.002352:0.002352:0.008032:0.008020:0.007702:0.003904
rative meta-analysis. :@0.101390:0.389446:0.221194:0.389446:0.221194:0.377171:0.101390:0.377171:0.003540:0.008032:0.003986:0.002352:0.006515:0.007644:0.003257:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003257
Lancet:@0.221194:0.389446:0.261069:0.389446:0.261069:0.377171:0.221194:0.377171:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986
. 2010; 375(9731):2073-81.:@0.261069:0.389446:0.403944:0.389446:0.403944:0.377171:0.261069:0.377171:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2. :@0.076190:0.400348:0.089220:0.400348:0.089220:0.388072:0.076190:0.388072:0.006515:0.003257:0.003257
Centers  for  Disease Control  and  prevention.  Chronic  Kidney  Dis-:@0.101390:0.400348:0.480956:0.400348:0.480956:0.388072:0.101390:0.388072:0.009560:0.007644:0.007173:0.003986:0.007644:0.003540:0.004563:0.003257:0.002317:0.003692:0.007702:0.003540:0.003257:0.002317:0.008749:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.005586:0.009560:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.003257:0.002317:0.008032:0.007173:0.008055:0.003257:0.002317:0.006961:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257:0.002305:0.009560:0.007173:0.003540:0.007702:0.007173:0.002352:0.007608:0.003257:0.002317:0.006950:0.002352:0.008055:0.007173:0.007644:0.006303:0.003257:0.002317:0.008749:0.002352:0.004574:0.003904
ease surveillance system – United states. website. http://www.cdc.:@0.101390:0.411249:0.480956:0.411249:0.480956:0.398974:0.101390:0.398974:0.007644:0.008032:0.004563:0.007644:0.002987:0.005856:0.007150:0.003540:0.006515:0.007644:0.002352:0.002352:0.002352:0.008032:0.007173:0.007608:0.007644:0.002999:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.002987:0.005880:0.002987:0.007702:0.007173:0.002352:0.003986:0.007644:0.008055:0.002987:0.005856:0.003986:0.008032:0.003986:0.007644:0.004563:0.003257:0.002987:0.009772:0.007644:0.008020:0.004563:0.002352:0.003986:0.007644:0.003257:0.002999:0.007173:0.003986:0.003986:0.008020:0.003257:0.005139:0.005139:0.009772:0.009772:0.009772:0.003257:0.007608:0.008055:0.007608:0.003257
gov/ckd:@0.101390:0.422151:0.150227:0.422151:0.150227:0.409875:0.101390:0.409875:0.007914:0.007702:0.006515:0.005139:0.007608:0.005903:0.008055
3. :@0.076190:0.433052:0.089220:0.433052:0.089220:0.420777:0.076190:0.420777:0.006515:0.003257:0.003257
Levin A, stevens pE. summary of KDIGO 2012 CKD Guideline: Be-:@0.101390:0.433052:0.480944:0.433052:0.480944:0.420777:0.101390:0.420777:0.005433:0.007644:0.006515:0.002352:0.007173:0.004762:0.008702:0.003257:0.004751:0.005856:0.003986:0.007644:0.006515:0.007644:0.007173:0.004563:0.004762:0.006961:0.006303:0.003257:0.004751:0.005856:0.007150:0.011030:0.011030:0.008032:0.003540:0.006303:0.004751:0.007702:0.003692:0.004751:0.006950:0.008749:0.002658:0.010254:0.010219:0.004762:0.006515:0.006515:0.006515:0.006515:0.004762:0.009560:0.006950:0.008749:0.004751:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.003257:0.004762:0.006750:0.007644:0.003904
hind the scenes, need for guidance, and a framework for moving :@0.101390:0.443954:0.484213:0.443954:0.484213:0.431678:0.101390:0.431678:0.007173:0.002352:0.007173:0.008055:0.003916:0.003986:0.007173:0.007644:0.003916:0.004563:0.007608:0.007644:0.007173:0.007644:0.004563:0.003257:0.003916:0.007173:0.007644:0.007644:0.008055:0.003916:0.003692:0.007702:0.003540:0.003916:0.007914:0.007150:0.002352:0.008055:0.008032:0.007173:0.007608:0.007644:0.003257:0.003916:0.008032:0.007173:0.008055:0.003916:0.008032:0.003916:0.003692:0.003540:0.008032:0.011030:0.007644:0.009772:0.007702:0.003540:0.005903:0.003916:0.003692:0.007702:0.003540:0.003916:0.011030:0.007702:0.006515:0.002352:0.007173:0.007914:0.003257
forward. :@0.101390:0.454855:0.152237:0.454855:0.152237:0.442580:0.101390:0.442580:0.003692:0.007702:0.003540:0.009772:0.008032:0.003540:0.008055:0.003257:0.003257
Kidney Int.:@0.152226:0.454855:0.211034:0.454855:0.211034:0.442580:0.152226:0.442580:0.006950:0.002352:0.008055:0.007173:0.007644:0.006303:0.003257:0.002658:0.007173:0.003986:0.003257
 2014 Jan;85(1):49-61.:@0.211022:0.454855:0.332424:0.454855:0.332424:0.442580:0.211022:0.442580:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.005668:0.008032:0.007173:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
4. :@0.076179:0.465757:0.089208:0.465757:0.089208:0.453481:0.076179:0.453481:0.006515:0.003257:0.003257
Gerstein HC, Mann JF, Yi Q, Zinman B, :@0.101379:0.465757:0.322065:0.465757:0.322065:0.453481:0.101379:0.453481:0.010254:0.007644:0.003540:0.004563:0.003986:0.007644:0.002352:0.007173:0.003904:0.008032:0.009560:0.003257:0.003916:0.010807:0.008032:0.007173:0.007173:0.003916:0.005668:0.005703:0.003257:0.003904:0.006961:0.002352:0.003916:0.010242:0.003257:0.003916:0.005644:0.002352:0.007173:0.011030:0.008032:0.007173:0.003916:0.006750:0.003257:0.003257
et al:@0.322723:0.465757:0.348640:0.465757:0.348640:0.453481:0.322723:0.453481:0.007644:0.003986:0.003904:0.008032:0.002352
. HOpE study investiga-:@0.348640:0.465757:0.480944:0.465757:0.480944:0.453481:0.348640:0.453481:0.003257:0.003916:0.008032:0.010219:0.006961:0.006303:0.003916:0.005856:0.003986:0.007150:0.008055:0.006303:0.003916:0.002352:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003904
tors.  Albuminuria and risk of  cardiovascular events,  death,  and :@0.101379:0.476658:0.484189:0.476658:0.484189:0.464383:0.101379:0.464383:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257:0.003034:0.008702:0.002352:0.008020:0.007150:0.011030:0.002352:0.007173:0.007150:0.003540:0.002352:0.008032:0.006303:0.008032:0.007173:0.008055:0.006303:0.003540:0.002352:0.004563:0.005903:0.006303:0.007702:0.003692:0.003257:0.003034:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.006303:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257:0.003034:0.008055:0.007644:0.008032:0.003986:0.007173:0.003257:0.003257:0.003034:0.008032:0.007173:0.008055:0.003257
heart failure in diabetic and nondiabetic individuals. :@0.101379:0.487560:0.409024:0.487560:0.409024:0.475284:0.101379:0.475284:0.007173:0.007644:0.008032:0.003540:0.003986:0.004351:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.004351:0.002352:0.007173:0.004351:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.002352:0.007608:0.004363:0.008032:0.007173:0.008055:0.004351:0.007173:0.007702:0.007173:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.002352:0.007608:0.004351:0.002352:0.007173:0.008055:0.002352:0.006515:0.002352:0.008055:0.007150:0.008032:0.002352:0.004563:0.003257:0.003257
JAMA.:@0.410141:0.487560:0.447277:0.487560:0.447277:0.475284:0.410141:0.475284:0.005668:0.008702:0.010807:0.008702:0.003257
 2001; :@0.447265:0.487560:0.484189:0.487560:0.484189:0.475284:0.447265:0.475284:0.004351:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
25;286(4):421-6.:@0.101379:0.498461:0.188879:0.498461:0.188879:0.486186:0.101379:0.486186:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
5. :@0.076179:0.509362:0.089208:0.509362:0.089208:0.497087:0.076179:0.497087:0.006515:0.003257:0.003257
Yusuf  s,  sleight  p, :@0.101379:0.509362:0.209670:0.509362:0.209670:0.497087:0.101379:0.497087:0.006961:0.007150:0.004563:0.007150:0.003692:0.003257:0.003046:0.005856:0.003257:0.003257:0.003046:0.005856:0.002352:0.007644:0.002352:0.007914:0.007173:0.003986:0.003257:0.003046:0.006961:0.003257:0.003257
et  al.:@0.212715:0.509362:0.244289:0.509362:0.244289:0.497087:0.212715:0.497087:0.007644:0.003986:0.003257:0.003046:0.008032:0.002352:0.003257
  Heart  Outcomes  prevention  Evaluation :@0.244289:0.509362:0.484201:0.509362:0.484201:0.497087:0.244289:0.497087:0.003257:0.003046:0.008032:0.007644:0.008032:0.003540:0.003986:0.003257:0.003046:0.010219:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257:0.003057:0.006961:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003257:0.003046:0.006303:0.006515:0.008032:0.002352:0.007150:0.008043:0.003986:0.002352:0.007702:0.007173:0.003257
study investigators. :@0.101367:0.520264:0.212809:0.520264:0.212809:0.507989:0.101367:0.507989:0.005856:0.003986:0.007150:0.008055:0.006303:0.003257:0.002352:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257
N Engl J Med. :@0.212809:0.520264:0.293713:0.520264:0.293713:0.507989:0.212809:0.507989:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2000 Jan;342(3):145-53.:@0.293689:0.520264:0.424864:0.520264:0.424864:0.507989:0.293689:0.507989:0.006515:0.006515:0.006515:0.006515:0.003257:0.005668:0.008032:0.007173:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
6. :@0.076167:0.531165:0.089196:0.531165:0.089196:0.518890:0.076167:0.518890:0.006515:0.003257:0.003257
pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-:@0.101367:0.531165:0.480909:0.531165:0.480909:0.518890:0.101367:0.518890:0.006961:0.007702:0.007914:0.007150:0.007644:0.003657:0.005668:0.003257:0.003657:0.006750:0.007702:0.004563:0.007608:0.007173:0.003657:0.005668:0.003257:0.003657:0.008749:0.008032:0.006515:0.002352:0.007644:0.004563:0.003669:0.007138:0.003257:0.003657:0.008749:0.008032:0.007914:0.007644:0.007173:0.008032:0.002352:0.004563:0.003669:0.010254:0.003257:0.003657:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.003657:0.007702:0.003692:0.003657:0.008032:0.007173:0.003657:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904
converting-enzyme inhibitor, ramipril, on cardiovascular events in :@0.101367:0.542067:0.484189:0.542067:0.484189:0.529791:0.101367:0.529791:0.007608:0.007702:0.007173:0.006515:0.007644:0.003540:0.003986:0.002352:0.007173:0.007914:0.003904:0.007644:0.007173:0.004998:0.006303:0.011030:0.007644:0.004974:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.003257:0.004974:0.003540:0.008032:0.011030:0.002352:0.008020:0.003540:0.002352:0.002352:0.003257:0.004986:0.007702:0.007173:0.004974:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004986:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.004986:0.002352:0.007173:0.003257
high-risk patients. :@0.101367:0.552968:0.201767:0.552968:0.201767:0.540693:0.101367:0.540693:0.007173:0.002352:0.007914:0.007173:0.003904:0.003540:0.002352:0.004563:0.005903:0.003257:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257
N Engl J Med:@0.201767:0.552968:0.276156:0.552968:0.276156:0.540693:0.201767:0.540693:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055
. 2000; 342(3):145-53:@0.276145:0.552968:0.389704:0.552968:0.389704:0.540693:0.276145:0.540693:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515
7. :@0.076167:0.563870:0.088961:0.563870:0.088961:0.551594:0.076167:0.551594:0.006397:0.003140:0.003257
seedat YK, Rayner BL, Veriava Y. south African hypertension practice :@0.101367:0.563870:0.484248:0.563870:0.484248:0.551594:0.101367:0.551594:0.005739:0.007526:0.007526:0.007937:0.007914:0.003869:0.002575:0.006844:0.006832:0.003140:0.002575:0.007020:0.007914:0.006185:0.007056:0.007526:0.003422:0.002575:0.006632:0.005315:0.003140:0.002575:0.008137:0.007526:0.003422:0.002234:0.007914:0.006397:0.007914:0.002575:0.006844:0.003140:0.002575:0.005739:0.007585:0.007032:0.003869:0.007056:0.002575:0.008584:0.003575:0.003422:0.002234:0.007491:0.007914:0.007056:0.002575:0.007056:0.006185:0.007902:0.007526:0.003422:0.003869:0.007526:0.007056:0.004445:0.002234:0.007585:0.007056:0.002575:0.007902:0.003422:0.007914:0.007491:0.003869:0.002234:0.007491:0.007644:0.003257
guideline 2014. :@0.101367:0.574771:0.188068:0.574771:0.188068:0.562496:0.101367:0.562496:0.007796:0.007032:0.002234:0.007937:0.007526:0.002234:0.002234:0.007056:0.007526:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.003257
Cardiovascular Journal of Africa.:@0.187950:0.574771:0.371183:0.574771:0.371183:0.562496:0.187950:0.562496:0.009443:0.007914:0.003422:0.007937:0.002234:0.007585:0.006397:0.007914:0.004445:0.007491:0.007032:0.002234:0.007914:0.003422:0.003140:0.005550:0.007585:0.007032:0.003422:0.007056:0.007914:0.002234:0.003140:0.007585:0.003575:0.003140:0.008584:0.003575:0.003422:0.002234:0.007491:0.007914:0.003257
 2014;25(6):288-94.:@0.371065:0.574771:0.472736:0.574771:0.472736:0.562496:0.371065:0.562496:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.006397:0.006397:0.004222:0.006397:0.004222:0.003140:0.006397:0.006397:0.006397:0.003786:0.006397:0.006397:0.003257
8. :@0.076167:0.585673:0.089196:0.585673:0.089196:0.573397:0.076167:0.573397:0.006515:0.003257:0.003257
Whelton pK, Carey RM, Aronow Ws, Casey DE Jr, Collins KJ, Den-:@0.101367:0.585673:0.480920:0.585673:0.480920:0.573397:0.101367:0.573397:0.011289:0.007173:0.007644:0.002352:0.003986:0.007702:0.007173:0.004610:0.006961:0.006950:0.003257:0.004610:0.009560:0.008032:0.003540:0.007644:0.006303:0.004621:0.007138:0.010807:0.003257:0.004621:0.008702:0.003540:0.007702:0.007173:0.007702:0.009772:0.004610:0.011289:0.005856:0.003257:0.004621:0.009560:0.008032:0.004563:0.007644:0.006303:0.004621:0.008749:0.006303:0.004621:0.005668:0.003540:0.003257:0.004610:0.009560:0.007702:0.002352:0.002352:0.002352:0.007173:0.004563:0.004621:0.006950:0.005668:0.003257:0.004610:0.008749:0.007644:0.007173:0.003904
nison Himmelfarb C, :@0.101367:0.596574:0.218042:0.596574:0.218042:0.584299:0.101367:0.584299:0.007173:0.002352:0.004563:0.007702:0.007173:0.002952:0.008032:0.002352:0.011030:0.011030:0.007644:0.002352:0.003692:0.008032:0.003540:0.008020:0.002963:0.009560:0.003257:0.003257
et al.:@0.217736:0.596574:0.245959:0.596574:0.245959:0.584299:0.217736:0.584299:0.007644:0.003986:0.002952:0.008032:0.002352:0.003257
 2017 ACC/AHA/AApA/ABC/ACpM/AGs/:@0.245959:0.596574:0.480944:0.596574:0.480944:0.584299:0.245959:0.584299:0.002952:0.006515:0.006515:0.006515:0.006515:0.002963:0.008702:0.009560:0.009560:0.005139:0.008702:0.008032:0.008702:0.005139:0.008702:0.008702:0.006961:0.008702:0.005139:0.008702:0.006750:0.009560:0.005139:0.008702:0.009560:0.006961:0.010807:0.005139:0.008702:0.010254:0.005856:0.005139
AphA/AsH/AspC/NMA/pCNA Guideline for the prevention, detec-:@0.101367:0.607476:0.480920:0.607476:0.480920:0.595200:0.101367:0.595200:0.008702:0.006961:0.007173:0.008702:0.005139:0.008702:0.005856:0.008032:0.005139:0.008702:0.005856:0.006961:0.009560:0.005139:0.008702:0.010807:0.008702:0.005139:0.006961:0.009560:0.008702:0.008702:0.003798:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.003834:0.003692:0.007702:0.003540:0.003822:0.003986:0.007173:0.007644:0.003822:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003257:0.003822:0.008055:0.007644:0.003986:0.007644:0.007608:0.003904
tion, evaluation, and management of high blood pressure in adults: :@0.101367:0.618377:0.484178:0.618377:0.484178:0.606102:0.101367:0.606102:0.003986:0.002352:0.007702:0.007173:0.003257:0.002728:0.007644:0.006515:0.008032:0.002352:0.007150:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.002728:0.008032:0.007173:0.008055:0.002728:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.002728:0.007702:0.003692:0.002728:0.007173:0.002352:0.007914:0.007173:0.002728:0.008020:0.002352:0.007702:0.007702:0.008055:0.002728:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.002728:0.002352:0.007173:0.002728:0.008032:0.008055:0.007150:0.002352:0.003986:0.004563:0.003257:0.003257
A report of the American College of Cardiology/American Heart :@0.101367:0.629279:0.484189:0.629279:0.484189:0.617003:0.101367:0.617003:0.008702:0.004704:0.003540:0.007644:0.008020:0.007702:0.003540:0.003986:0.004704:0.007702:0.003692:0.004704:0.003986:0.007173:0.007644:0.004704:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.004704:0.009560:0.007702:0.002352:0.002352:0.007644:0.007914:0.007644:0.004704:0.007702:0.003692:0.004704:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.002352:0.007702:0.007914:0.006303:0.005139:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.004704:0.008032:0.007644:0.008032:0.003540:0.003986:0.003257
Association task force on clinical practice guidelines. :@0.101367:0.640180:0.403827:0.640180:0.403827:0.627905:0.101367:0.627905:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.002975:0.003986:0.008032:0.004563:0.005903:0.002975:0.003692:0.007702:0.003540:0.007608:0.007644:0.002963:0.007702:0.007173:0.002975:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.002987:0.008020:0.003540:0.008032:0.007608:0.003986:0.002352:0.007608:0.007644:0.002975:0.007914:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.003257:0.003257
Hypertension.:@0.403544:0.640180:0.480932:0.640180:0.480932:0.627905:0.403544:0.627905:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257
 :@0.480932:0.640180:0.484189:0.640180:0.484189:0.627905:0.480932:0.627905:0.003257
2017.:@0.101367:0.651082:0.130683:0.651082:0.130683:0.638806:0.101367:0.638806:0.006515:0.006515:0.006515:0.006515:0.003257
9. :@0.076167:0.661983:0.089196:0.661983:0.089196:0.649708:0.076167:0.649708:0.006515:0.003257:0.003257
Klug E, Raal FJ, Marais AD, smuts CM, :@0.101367:0.661983:0.311246:0.661983:0.311246:0.649708:0.101367:0.649708:0.006950:0.002352:0.007150:0.007914:0.002611:0.006303:0.003257:0.002611:0.007138:0.008032:0.008032:0.002352:0.002611:0.005703:0.005668:0.003257:0.002611:0.010807:0.008032:0.003540:0.008032:0.002352:0.004563:0.002611:0.008702:0.008749:0.003257:0.002611:0.005856:0.011030:0.007150:0.003986:0.004563:0.002611:0.009560:0.010807:0.003257:0.003257
et al.:@0.310599:0.661983:0.338480:0.661983:0.338480:0.649708:0.310599:0.649708:0.007644:0.003986:0.002611:0.008032:0.002352:0.003257
 south African dyslipidae-:@0.338480:0.661983:0.480932:0.661983:0.480932:0.649708:0.338480:0.649708:0.002611:0.005856:0.007702:0.007150:0.003986:0.007173:0.002611:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.002611:0.008055:0.006303:0.004563:0.002352:0.002352:0.008020:0.002352:0.008055:0.008032:0.007667:0.003904
mia guideline consensus statement: 2018 update. A joint statement :@0.101367:0.672884:0.484189:0.672884:0.484189:0.660609:0.101367:0.660609:0.011030:0.002352:0.008032:0.002940:0.007914:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.002940:0.007608:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.002940:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.002940:0.006515:0.006515:0.006515:0.006515:0.002952:0.007150:0.008020:0.008055:0.008032:0.003986:0.007644:0.003257:0.002940:0.008702:0.002940:0.002387:0.007702:0.002352:0.007173:0.003986:0.002940:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257
from the south African Heart Association (sA Heart) and the Lipid :@0.101367:0.683786:0.484178:0.683786:0.484178:0.671511:0.101367:0.671511:0.003692:0.003540:0.007702:0.011030:0.004304:0.003986:0.007173:0.007644:0.004316:0.005856:0.007702:0.007150:0.003986:0.007173:0.004304:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.004304:0.008032:0.007644:0.008032:0.003540:0.003986:0.004316:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.004316:0.004339:0.005856:0.008702:0.004316:0.008032:0.007644:0.008032:0.003540:0.003986:0.004339:0.004316:0.008032:0.007173:0.008055:0.004316:0.003986:0.007173:0.007644:0.004304:0.005433:0.002352:0.008020:0.002352:0.008055:0.003257
and Atherosclerosis society of southern Africa (LAssA). :@0.101367:0.694687:0.414163:0.694687:0.414163:0.682412:0.101367:0.682412:0.008032:0.007173:0.008055:0.003199:0.008702:0.003986:0.007173:0.007632:0.003540:0.007702:0.004563:0.007608:0.002352:0.007644:0.003540:0.007702:0.004563:0.002352:0.004563:0.003199:0.005856:0.007702:0.007608:0.002352:0.007644:0.003986:0.006303:0.003199:0.007702:0.003692:0.003199:0.005856:0.007702:0.007150:0.003986:0.007173:0.007644:0.003528:0.007173:0.003199:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.003199:0.004339:0.005433:0.008702:0.005856:0.005856:0.008702:0.004339:0.003257:0.003257
S Afr Med J.:@0.414104:0.694687:0.480920:0.694687:0.480920:0.682412:0.414104:0.682412:0.005856:0.003199:0.008702:0.003692:0.003540:0.003199:0.010807:0.007644:0.008055:0.003199:0.005668:0.003257
 :@0.480920:0.694687:0.484178:0.694687:0.484178:0.682412:0.480920:0.682412:0.003257
2018;108(11b):973-1000.:@0.101367:0.705589:0.235975:0.705589:0.235975:0.693314:0.101367:0.693314:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.008020:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
10.  sEMDsA 2017 Guidelines for the Management of Type 2 diabetes :@0.076167:0.716490:0.484166:0.716490:0.484166:0.704215:0.076167:0.704215:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.006303:0.010807:0.008749:0.005856:0.008702:0.004374:0.006515:0.006515:0.006515:0.006515:0.004374:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.004374:0.003692:0.007702:0.003540:0.004363:0.003986:0.007173:0.007644:0.004363:0.010807:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.004363:0.007702:0.003692:0.004363:0.005009:0.006303:0.008020:0.007644:0.004374:0.006515:0.004374:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257
mellitus. :@0.101367:0.727392:0.149309:0.727392:0.149309:0.715116:0.101367:0.715116:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.003257
JEMDSA :@0.149309:0.727392:0.198651:0.727392:0.198651:0.715116:0.149309:0.715116:0.005668:0.006303:0.010807:0.008749:0.005856:0.008702:0.003257
2017;22:s1-s192:@0.198651:0.727392:0.285928:0.727392:0.285928:0.715116:0.198651:0.715116:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.005856:0.006515:0.003904:0.005856:0.006515:0.006515:0.006515
11.  Wanner C, Lachin JM, Inzucchi sE, Fitchett D, :@0.076167:0.738293:0.358859:0.738293:0.358859:0.726018:0.076167:0.726018:0.006515:0.006515:0.003257:0.003257:0.005656:0.011289:0.008032:0.007173:0.007173:0.007644:0.003540:0.003210:0.009560:0.003257:0.003210:0.005433:0.008032:0.007608:0.007173:0.002352:0.007173:0.003210:0.005668:0.010807:0.003257:0.003210:0.002658:0.007173:0.004998:0.007150:0.007608:0.007608:0.007173:0.002352:0.003222:0.005856:0.006303:0.003257:0.003210:0.005703:0.002352:0.003986:0.007608:0.007173:0.007644:0.003986:0.003986:0.003210:0.008749:0.003257:0.003257
et al:@0.358824:0.738293:0.384048:0.738293:0.384048:0.726018:0.358824:0.726018:0.007644:0.003986:0.003210:0.008032:0.002352
. EMpA-REG OUT-:@0.384048:0.738293:0.480932:0.738293:0.480932:0.726018:0.384048:0.726018:0.003257:0.003210:0.006303:0.010807:0.006961:0.008702:0.003904:0.007138:0.006303:0.010254:0.003210:0.010219:0.007702:0.005009:0.003904
COME investigators. Empagliflozin and clinical outcomes in patients :@0.101379:0.749195:0.484201:0.749195:0.484201:0.736919:0.101379:0.736919:0.009560:0.010219:0.010807:0.006303:0.002775:0.002352:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003986:0.007702:0.003540:0.004563:0.003257:0.002775:0.006303:0.011030:0.008020:0.008032:0.007914:0.002352:0.002352:0.002852:0.002852:0.007702:0.004998:0.002352:0.007173:0.002775:0.008032:0.007173:0.008055:0.002775:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.002775:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.002763:0.002352:0.007173:0.002775:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257
with type 2 diabetes mellitus, established cardiovascular disease, :@0.101379:0.760096:0.484201:0.760096:0.484201:0.747821:0.101379:0.747821:0.009772:0.002352:0.003986:0.007173:0.004751:0.003986:0.006303:0.008020:0.007644:0.004751:0.006515:0.004751:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.004751:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.004751:0.007644:0.004563:0.003986:0.008032:0.008020:0.002352:0.002352:0.004574:0.007173:0.007644:0.008055:0.004751:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004751:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.003257
and chronic kidney disease. :@0.101379:0.770998:0.264362:0.770998:0.264362:0.758722:0.101379:0.758722:0.008032:0.007173:0.008055:0.003257:0.007608:0.007173:0.003540:0.007702:0.007173:0.002352:0.007608:0.003257:0.005903:0.002352:0.008055:0.007173:0.007644:0.006303:0.003257:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.003257
Circulation.:@0.264350:0.770998:0.329414:0.770998:0.329414:0.758722:0.264350:0.758722:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257
 2018;137(2):119-129.:@0.329414:0.770998:0.446230:0.770998:0.446230:0.758722:0.329414:0.758722:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257